Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 6Other solid neoplasm 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 14Carcinoma, Non-Small-Cell Lung 8Head and Neck Neoplasms 5Carcinoma, Renal Cell 5Triple Negative Breast Neoplasms 3Skin Neoplasms 2Colorectal Neoplasms 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Motor Activity 1Mesothelioma, Malignant 1Lung Neoplasms 1Kidney Neoplasms 1Gastrointestinal Neoplasms 1Carcinoma, Transitional Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 14Nivolumab 10atezolizumab 5durvalumab 4Ipilimumab 4Docetaxel 4Cyclophosphamide 4avelumab 3Specimen Handling 3Radiosurgery 3Magnetic Resonance Spectroscopy 3temsirolimus 2poly ICLC 2fludarabine 2epacadostat 2enzalutamide 2cabozantinib 2budigalimab 2aldesleukin 2abiraterone 2Radiotherapy 2Interleukin-2 2Gemcitabine 2venetoclax 1utomilumab 1trastuzumab deruxtecan 1tislelizumab 1spartalizumab 1sargramostim 1rovalpituzumab tesirine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Immune Checkpoint Inhibitors × Dermatologic × Clear all
NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡